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This study evaluated whether statin therapy changed a diagnostic validity of lipid and inﬂammatory markers in ischemic heart
disease (IHD) patients. Levels of lipids, lipoproteins, apolipoproteins, inﬂammatory markers, and atherogenic indexes were
determined in 49 apparently healthy men and women, 82 patients having stable angina pectoris (SAP), 80 patients with unstable
angina (USAP), and 106 patients with acute ST-elevation myocardial infarction (STEMI) treated or not treated with statins.
Diagnostic accuracy of markers was determined by ROC curve analysis. Signiﬁcantly lower apoA-I in all statin-treated groups
and signiﬁcantly higher apoB in statin-treated STEMI group compared to non-statin-treated groups were observed. CRP showed
the best ROC characteristics in the assessment of STEMI patients. Lp(a) is better in the evaluation of SAP and USAP patients,
considering that Lp(a) showed the highest area under the curve (AUC). Regarding atherogenic indexes, the highest AUC in SAP
group was obtained for TG/apoB and in USAP and STEMI patients for TG/HDL-c. Statins lowered total cholesterol, LDL-c, and
TG but fail to normalize apoA-I in patients with IHD.
1.Introduction
Beside endothelial dysfunction leading to inﬂammatory
reaction,lipidmetabolismdisordersrepresentthesecondkey
event in the initiation and rapid development of atheroge-
nesis [1]. Many individual lipid and inﬂammatory markers
have been considered as the factors playing an important
role in atherogenesis and prognosis of related diseases.
The atherogenic dyslipidemic proﬁle, especially mild to
marked elevation of apo-B containing lipoproteins, such
as very low-density lipoproteins (VLDL), VLDL-remnants,
intermediate-density lipoproteins (IDL), and low-density
lipoproteins (LDL) (speciﬁcally small, dense LDL), and low
levels of high-density lipoproteins (HDL) [2–4], appears
to promote enhanced arterial cholesterol deposition and
accelerate the progression of atherosclerotic disease. Despite
the use of new and eﬀective pharmacological drugs to lower
plasma lipid concentration, cardiovascular diseases continue
to be the main cause of death in western countries [5,
6]. Fenoﬁbrate lowers the plasma level of cholesterol and
triglyceride, corrects the abnormality in LDL metabolism,
but has no eﬀect on HDL-cholesterol (HDL-c) [7]. On
the other hand, statins have a therapeutic eﬀect on lipid
metabolism and inﬂammation. They lower total and LDL-
cholesterol (LDL-c), elevate HDL-c, and lower inﬂammatory
m a r k e r ss u c ha sC - r e a c t i v ep r o t e i n( C R P )[ 8–11]. Since
antilipidemic drugs induce modiﬁcations in current lipid
metabolism and inﬂammatory response, lipid and inﬂam-
matory markers become less convenient in assessing the
activity of atherosclerotic process. This may be a reason for
contradictory results related to CRP, which was until recently
a promising marker in predicting cardiovascular events.
Recent limited data have shown that lipoprotein(a) (Lp(a))
and the ratio of Tc/HDL-c may be used as much stronger2 Cardiology Research and Practice
predictors in screening for high blood lipid [12], and Lp(a)
is the best single marker for the presence of cerebrovascular
disease [13].
The aim of this study was to determine which individual
lipid or inﬂammatory biomarkers had the highest clinical
accuracy by Receiver Operating Characteristic (ROC) curve
analysis in patients with diﬀerent stages of ischemic heart
disease treated or not treated with statins.
2.MaterialsandMethods
2.1. Subject. The study evaluated patients admitted to the
Institute for Cardiovascular diseases “Niˇ ska Banja” for the
evaluation of chest pain. Patients were categorized into three
groups based on the degree of ischemic heart disease (IHD):
chronic stable angina pectoris (SAP group), unstable angina
pectoris (USAP group), and acute ST-elevation myocardial
infarction (STEMI group). The SAP group consisted of 52
male and 30 female (total 82, mean age 61.3±6.5 years);
the USAP group had 50 male and 30 female (total 80 mean
age 60.8±9.8 years); the STEMI patients included 72 male
and 34 female (total 106, mean age 60.22±12.7 years). Each
group was divided into statin-treated (+) and non-statin-
treated (−) groups. The SAP(+) group consisted of 34 males
and 17 females, the SAP(−) of 18 males and 13 females, the
USAP(+) of 35 males and 12 females, the USAP(−)o f1 5
males and 18 females, the STEMI(+) of 37 males and 18
females, and the STEMI(−) of 35 males and 16 females.
The patients in the SAP group gave a history consistent
with stable angina for at least 3 months before entering
the study and demonstrated objective evidence of ischemia
on exercise electrocardiogram and/or stress echocardiogram.
None of the patients in this group had previous myocardial
infarction or myocardial revascularization, cardiac valve
disease, cardiomyopathy, malignant arrhythmias, acute or
chronic liver disease, renal failure, or inﬂammatory disease,
and none of the patients were under consideration for
coronary revascularization at the time of the inclusion into
the study.
Unstable angina was deﬁned according to Hamm and
Braunwald [14]. All patients in the USAP group had chest
pain of increasing frequency and severity or at rest during
the last 48 hours before hospitalisation associated with ST
segment changes, T wave changes, or both and without rise
in cardiac enzymes and troponin I.
Acute myocardial infarction was based on the following
criteria: chest pain persisting longer than 30 min, concomi-
tant changes on the electrocardiogram at the admission to
hospital and elevated troponin I levels. All patients had
STEMI according to the Guidelines of the European Society
of Cardiology [15]. In all patients, a detailed clinical analysis
was performed just after admission, and all of them were
asked for current medications. Additional explanation of the
criteria for patients with ischemic heart disease selection was
given in our previously published paper [16].
For the control group, we recruited 49 (30 male, 19
female) healthy volunteers—blood bank donors from the
DepartmentforBloodTransfusionoftheClinicalCentreNiˇ s.
All controls were free of any acute infectious disease and any
history of hypertension, diabetes or ischemic heart disease.
All subjects gave informed consent prior to their enrolment
in the study, and the study was approved by the local Ethics
Committee.
2.2. Methods. Blood samples were obtained within 24 hours
after admission after overnight fasting. Peripheral venous
blood was drown into vacutainer tubes containing ethylene
diamine-tetracetic acid (EDTA), citrate, or no anticoagulant.
Troponin I and inﬂammatory markers were determined
in serum, ﬁbrinogen in citrate plasma, and lipid markers
in EDTA plasma. Aliquots of plasma and serum for the
determinationofneopterin,iNOS,NO2/NO3,TNF -α,Lp(a),
andoxidizedLDL(oxLDL)werestoredat80◦Cuntilassayed.
All other analyses were performed the same day the blood
was collected.
Troponin I was determined on AxSYM (Abbott Ireland
Diagnostics Division, Lisnamuck, Ireland). The diagnostic
cutoﬀ for acute myocardial infarction is 0.40ng/mL. In
apparentlyhealthypopulation,99thpercentileis0.04ng/mL.
Depending on patient hours after admission, sensitivity
ranges from 60% (0–6h) to 91.7% (12–24h), and speciﬁcity
97.4% to 98.3%.
HsCRP, total cholesterol (Tc), triglycerides (TG), LDL-
c, HDL-c, apolipoprotein A-I (ApoA-I), apolipoprotein
B (ApoB) were assayed on analyzer AU 400 (Olympus,
Tokio, Japan). HsCRP was measured using a latex-enhanced
immunoturbidimetric method on Olympus AU400. hsCRP
reference values are <1mg/L (manufacturer recommenda-
tion).Thistestislinearwithinaconcentrationrangeof0.08–
80mg/L.Theintra-assayprecisionforthreediﬀerentsamples
are between CV% 0.55 and CV% 4.32. Tc, TG, HDL-c, and
LDL-c were measured by routine methods on analyzer AU
400.ApoA-IandapoBconcentrationsweredeterminedusing
an immunoturbidimetric method (Olympus, Tokio, Japan).
The plasma concentration of Lp(a) was also assayed
by a latex immunoassay (Sentinel CH Srl Diagnostics,
Milan, Italy) on Olympus AU400. Lower detection limit
was 3 mg/dL and the reference values were <30mg/dL. The
performance characteristics of Lp(a) test were as follows:
the measuring range was 3.0–130mg/dL; the intra-assay pre-
cision determined in two levels was CV% 2.00 and 1.26,
respectively.
Serum neopterin concentrations were determined using
a commercially available immunoassay (ELISA kit, IBL,
Hamburg, Germany). The limit of detection was 0.7nmol/L.
Serum iNOS activity was measured by a commercially
available Quantikine human iNOS immunoassay (ELISA kit,
R&D Systems Europe, LTD. UK). The limit of detection was
0.15U/mL.
Quantikine human TNF-α immunoassay (R&D Systems
Europe, Ltd. UK) was used for the estimation of serum TNF-
α concentration.
Serum NO2/NO3 concentration was measured by the
modiﬁed cadmium-reduction method of Navaro-Gonz´ alvez
et al. [17] which is based on the produced nitrite deter-
mination by diazotization of sulfanilamide and coupling
to naphthylene diamine. The lower and upper detectionCardiology Research and Practice 3
Table 1: Demographic characteristics and blood lipid and inﬂammatory markers in patients with ischemic heart disease.
SAP USAP STEMI Controls
Male/female (N) 52/30 50/30 72/34 30/19
Age years 61.3 ±6.56 0 .8 ±9.86 0 .2 ±12.75 9 .1 ±9.7
Troponin I, ng/mL 0.0 (0.0–1.68) 0.03 (0.0–3.7)
∗ 12.8 (0.0–159.6)
∗∗∗ 0.0 (0.0–0.01)
TG, mmol/L 1.88 (0.58–21.4)
∗ 2.08 (0.56–7.6)
∗∗∗ 1.90 (0.56–4.9)
∗ 1.30 (0.46–4.18)
Tc, mmol/L 5.60 ±1.20 5.78 ±1.72 5.91 ±1.57 5.48 ±0.49
HDL-c, mmol/L 1.16 ±0.28 1.00 ±0.31
∗∗∗ 1.06 ±0.26
∗∗∗ 1.15 ±0.28
LDL-c, mmol/L 3.47 ±1.05 3.55 ±1.40 3.88 ±1.28 3.51 ±0.59
Lp(a), mg/dL 14.4 (3.6–67.8)
∗∗∗ 22.7 (5.9–88.9)
∗∗∗ 17.8 (4.8–79.0)
∗∗∗ 5.6 (2.9–19.7)
ApoA-I, g/L 1.13 ±0.30
∗∗∗ 1.04 ±0.29
∗∗∗ 1.11 ±0.17
∗∗∗ 1.34 ±0.21
ApoB, g/L 1.06 ±0.38 1.17 ±0.40 1.25 ±0.31 1.17 ±0.14
oxLDL, ng/mL 211 (11.7–1925) 143 (7–1550)
∗ 140 (15–2105) 195 (18–705)
hsCRP, g/L 3.0( 0 .4–84.35)
∗ 5.8( 0 .43–178.3)
∗∗,b 18.0 (0.56–270)
∗∗∗,c 1.5 (0.1–16.5)
Fibrinogen, g/L 4.29 ±1.22 5.03 ±1.49
∗∗ 5.06 ±2.46
∗ 3.92 ±1.03
Neopterin, nmol/L 14.9 (3–57)
∗∗∗ 14.3 (1–105)
∗∗,a 13.0 (1–52) 13.4 (1–19.6)
iNOS, U/mL 2.2 (0.5–4.7) 2.9 (0.9–6.0) 3.0 (0.9–6.2) 2.2 (0.6–9.3)
NO2/NO3, μmol/L 96 (35–197) 125 (52–199)
∗∗,b 102 (61–243) 97 (57–230)
TNF-α,p g / m L 1 2 .74 ±1.25 13.78 ±1.93 14.47 ±2.15 13.60 ±2.19
Theresults are presentedasmeans±SDforparametric,andmedian(min–max)for nonparametricvalues ∗P<. 05 versus controls, ∗∗P<. 01 versus controls,
∗∗∗P<. 001 versus controls, aP<. 05 versus STEMI, bP<. 01 versus SAP, cP<. 001 versus SAP.
limits were 2 and 250 μmol/L, respectively. Plasma oxLDL
concentrations were estimated by a commercially available
ELISA kit (Immune diagnostic AG, Bensheim).
2.3. Statistical Analysis. Most statistics were performed using
SPSS (the Statistical Package for the Social Sciences) com-
puter program. The comparison of the diﬀerent patient
groups to the control group was performed using ANOVA
followed by a 2-sided Dunnett’s test (for multiple compar-
isons), or Student’s nonpaired t-test as appropriate. The
clinical accuracy of the examined parameters was assessed
using receiver operating characteristic (ROC) curve analysis.
ROC plots were constructed, and the areas under the curves
(AUC), standard errors, 95% conﬁdence interval, sensitivity,
a n ds p e c i ﬁ c i t ya sw e l la so p t i m a lc u t o ﬀ were calculated using
MedCalc computer program. Cutoﬀ values at which the
discrimination between the cases with positive and negative
diagnosis was optimal were set. The comparisons of the areas
under diﬀerent ROC plots were made using univariate z
scores. Multinomial logistic regression was used to assess
wich of the lipid and inﬂammatory markers showing high
sensitivity and speciﬁcity may be the best predictor of SAP,
USAP or STEMI.
3. Results
Demographic characteristics in the studied patients showed
the prevalence of males in all groups. The average age
of groups was about sixty (Table 1). Statistical analysis
using ANOVA showed that SAP patients had signiﬁcantly
higher concentrations of TG, Lp(a), hsCRP, neopterin, and
signiﬁcantly lower levels of apoA-I in comparison with
healthysubjects.InadditiontotheseparametersintheUSAP
group, three more markers were signiﬁcantly increased,
including troponin I, NO2/NO3 and ﬁbrinogen, while HDL-
c and oxLDL were decreased. In STEMI patients signiﬁcant
diﬀerences were observed in troponin I, TG, HDL-c, Lp(a),
apoA-I, hsCRP and ﬁbrinogen. Also, signiﬁcant diﬀerences
w e r ef o u n di nh s C R P ,n e o p t e r i na n dN O 2/NO3 between
diﬀerent patient groups (Table 1).
However, the testing between statin-treated and non-
statin-treated groups showed fewer diﬀerences. None of
all studied inﬂammatory markers showed any signiﬁcant
diﬀerence between statin-treated and non-statin-treated
groups (Table 2). Among lipid markers only apoA-I levels
were signiﬁcantly decreased in SAP(+)compared to SAP(−)
patients. A signiﬁcant decrease in apoA-I, HDL-c, and LDL-
c/apoB was noted in USAP(+) patients, as well as a signiﬁ-
cant increase in apoB/apoA-I, LDL-c/HDL-c, and Tc/HDL-
c, in comparison with the USAP(−) group. STEMI(+)
patients showed a signiﬁcant decrease in apoA-I and
LDL-c/apoB and an increase in apoB, apoB/apoA-I, LDL-
c/HDL-c and Tc/HDL-c compared to STEMI(−) patients
(Table 3).
Since we did not ﬁnd any signiﬁcant diﬀerence in ROC
curve analysis between statin-treated and non-statin-treated
groups in any individual inﬂammatory or lipid marker,
ROC curve analysis included both subgroups of each patient
group.
The ROC curves for inﬂammatory markers are presented
in Figure 2. In SAP patients no biomarker showed a signiﬁ-
cant diﬀerence related to any other although hsCRP had the
highest area under the ROC (0.691 ± 0.079) (Table 4). The
greatest sensitivity was found for NO2/NO3 (81.0%), TNF-α
(88.0%), and neopterin (88.6%), but their speciﬁcities were
low (30.4%, 42.1%, and 42.9%, resp.).4 Cardiology Research and Practice
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Table 4: The results of ROC curves analysis of inﬂammatory markers in ischemic heart disease patients.
AUC SE 95%CI Speciﬁcity Sensitivity Criterion
SAP
CRP 0.691 0.079 0.533–0.821 66.7 72.7 >1.9
Fibrinogen 0.557 0.087 0.399–0.706 59.5 75.9 >3.9
iNOS 0.558 0.087 0.400–0.707 78.9 48.0 >2.8
Neopterin 0.642 0.086 0.484–0.781 42.9 88.6 >11.9
NO2/NO3 0.567 0.087 0.410–0.716 30.4 81.0 ≤122.0
TNF-α 0.596 0.088 0.437–0.741 42.1 88.0 ≤14.0
USAP
CRP 0.808∗ 0.074 0.643–0.919 87.2 69.8 >4.1
Fibrinogen 0.680 0.090 0.504–0.825 59.5 90.5 >3.9
iNOS 0.610 0.095 0.433–0.767 78.9 52.6 >2.8
Neopterin 0.709 0.086 0.534–0.848 94.3 34.9 >18.9
NO2/NO3 0.698 0.088 0.523–0.839 47.8 92.7 >88.6
TNF-α 0.548 0.097 0.374–0.714 31.6 94.7 >11.9
STEMI
CRP 0.923
∗∗ 0.043 0.796–0.982 89.7 88.6 >4.7
Fibrinogen 0.562 0.090 0.399–0.716 91.9 52.2 >5.0
iNOS 0.602 0.088 0.437–0.751 21.1 100.0 >0.9
Neopterin 0.725 0.081 0.563–0.852 100.0 19.0 >19.6
NO2/NO3 0.627 0.087 0.462–0.772 47.8 74.4 >88.6
TNF-α 0.604 0.088 0.439–0.753 89.5 27.3 >15.5
∗P<. 05 versus TNF-α, ∗∗P<. 05 to P<. 001 versus all other markers.
Also, in USAP patients AUC for hsCRP was the highest
(0.808 ± 0.074), and signiﬁcantly higher only in comparison
with TNF-α (0.548 ± 0.097). Fibrinogen, NO2/NO3,a n d
TNF-α showed very high sensitivity (90.5%, 92.7%, and
94.7%, resp.) for optimal cutoﬀ values, and low speciﬁcity
(under 59.5%). Neopterin showed high speciﬁcity (94.3%),
and rather poor sensitivity (34.9%). The best predictor for
disease activity was CRP with speciﬁcity of 87.2%, and
sensitivity 69.8% when the cutoﬀ was >4.1mg/L.
In the STEMI group, ROC for hsCRP (0.923 ± 0.043)
was signiﬁcantly higher in comparison with all others. The
highest sensitivity was obtained for iNOS (100%), but very
low speciﬁcity (21.1%) excluded this marker from clinical
use. Due to good sensitivity (88.6%) and speciﬁcity (89.7%)
for cutoﬀ >4.7, CRP alone may be satisfactory for patient
screening.
The results related to ROC curves of lipid markers were
shown in Figure 1 and Table 5. The highest AUC in SAP
patients was obtained for Lp(a) (0.835 ± 0.049), which
is signiﬁcantly higher than AUC for oxLDL, LDL-c and
apoB (P<. 001). ApoA-I also had the AUC (0.780 ±
0.065) signiﬁcantly higher than AUC for oxLDL and LDL-
c( P<. 05). However, sensitivity (81.8%), and speciﬁcity
(80.0%) of Lp(a) were higher compared to all the other lipid
markers.
In patients with USAP the highest AUCs were observed
for Lp(a) (0.951 ± 0.025, signiﬁcantly higher in comparison
with LDL-c, oxLDL, apoB and TG), and apoA-I (0.876 ±
0.051, signiﬁcantly higher than apoB and oxLDL AUCs).
Sensitivity and speciﬁcity for Lp(a) were very high (97.9%
and 84.0%, resp.), while for apoA-I these values were 91.3%
and 71.8%, respectively. So, these markers may be useful
in assessing disease activity in more than 90% of patients.
No diﬀerence between the ability of Lp(a) and apoA-I to
correctly stratify the patients was found.
Further, in STEMI patients both Lp(a) and apoA-I had
also the highest AUC in comparison with other studied
markers. For Lp(a) AUC was 0.881 and statistically diﬀerent
in comparison with apoB, LDL-c, oxLDL (P<. 001) and
TG (P<. 01), and for apoA-I it was 0.836 (signiﬁcantly
higher than AUCs for LDL-c and oxLDL; P<. 001). OxLDL,
apoB and LDL-c showed high speciﬁcity (96.7%, 89.7% and
87.2%, resp.), but very poor sensitivity (24.5%, 30.9%, and
25.5%,resp.),whichmadethemunsatisfactoryfordiagnostic
screening. Thus, Lp(a) with 84.9% sensitivity and 84.0%
speciﬁcitystayedthebestpredictor,betterthanapoA-Iwhose
sensitivity was 83.6% and speciﬁcity 71.8%.
Since hsCRP showed the best characteristics among all
studied inﬂammatory markers, and Lp(a) was the best lipid
marker, we compared these two and troponin I in patient
groups and showed that (Table 6) there was a signiﬁcant
diﬀerence between their AUCs in USAP patients in whom
AUC for Lp(a) was 0.957 (P<. 05) in comparison with 0.859
for hsCRP AUC and 0.821 for troponin I AUC (P = .015).
In SAP patients, there was no signiﬁcant diﬀerence in AUC
between the diﬀerent markers although hsCRP AUC and
Lp(a) AUC were signiﬁcantly higher ((P<. 05), P<. 01,
resp.) than AUC for troponin I.
Generally, almost all atherogenic indexes showed accept-
able discriminative ability for ischemic heart disease patients
(Figure 3, Table 7). The ratio of TG to apoB had the highest
AUC (0.89 ± 0.03) and signiﬁcantly higher than AUCs for
apoB/apoA (0.71 ± 0.06), LDL-c/apoB (0.77 ± 0.06), LDL-
c/HDL-c (0.65 ± 0.06), and Tc/HDL-c (0.73 ± 0.06) in SAP
patients. A similar relationship was observed for TG/HDL-
c with AUC of 0.88 ± 0.04. Identical AUCs were foundCardiology Research and Practice 7
Table 5: The results of ROC curves analysis of lipid markers in ischemic heart disease patients.
AUC SE 95%CI Speciﬁcity Sensitivity Criterion
SAP
ApoA-I 0.780a 0.065 0.660–0.873 71.8 77.3 ≤1.28
ApoB 0.542b 0.076 0.414–0.666 92.3 38.6 ≤0.9
LDL-c 0.539b 0.076 0.411–0.664 87.2 40.9 ≤3.06
Lp(a) 0.835c 0.049 0.722–0.915 80.0 81.8 >8.2
oxLDL 0.552 0.075 0.423–0.675 80.0 43.2 >280
TG 0.704 0.065 0.578–0.811 48.7 86.4 >1.31
USAP
ApoA-I 0.876C 0.051 0.773–0.944 71.8 91.3 ≤1.28
ApoB 0.557 0.074 0.430–0.678 89.7 21.7 >1.41
LDL-c 0.588 0.075 0.461–0.707 64.1 60.9 ≤3.49
Lp(a) 0.951B 0.025 0.869–0.988 84.0 97.9 >8.2
oxLDL 0.529 0.075 0.403–0.652 93.3 32.6 >460
TG 0.742A 0.060 0.621–0.841 71.8 69.6 >1.94
STEMI
ApoA-I 0.836
∗∗∗∗ 0.057 0.732–0.911 71.8 83.6 ≤1.26
ApoB 0.626
∗∗ 0.068 0.506–0.735 89.7 30.9 >1.41
LDL-c 0.514 0.073 0.395–0.631 87.2 25.5 ≤3.07
Lp(a) 0.881
∗∗∗/∗∗∗∗∗ 0.038 0.785–0.994 84.0 84.9 >8.2
oxLDL 0.505 0.074 0.387–0.623 96.7 24.5 >4.80
TG 0.664∗ 0.065 0.546–0.769 56.4 69.1 >1.49
aP<. 05 versus LDL-c and oxLDL, bP<. 05 versus TG, cP<. 001 versus oxLDL, LDL-c and ApoB, AP<. 05 versus ApoB and OxLDL, BP<. 001 versus LDL-c,
oxLDL, ApoB and TG, CP<. 001 versus ApoB, LDL-c and oxLDL, ∗P<. 05 versus ApoA, LDL-c, ∗∗P<0.01 versus ApoA, LDL-c, ∗∗∗P<. 01 versus TG,
∗∗∗∗P<. 001 versus LDL-c, oxLDL, ∗∗∗∗∗P<. 001 versus ApoB, LDL-c, OxLDL.
Table 6: Comparison of CRP and Lp(a) and troponin I ROC curves analysis.
AUC SE 95%CI Speciﬁcity Sensitivity Cutoﬀ
SAP
CRP 0.758
∗∗ 0.057 0.640–0.853 57.6 75.7 >1.9
Lp(a) 0.843
∗∗∗ 0.046 0.736–0.919 80.0 81.8 >8.2
Troponin I 0.568 0.049 0.480–0.654 96.9 17.6 >0
USAP
CRP 0.859 0.043 0.750–0.930 87.2 69.8 >4.1
Lp(a) 0.957∗ 0.023 0.880–0.990 84.0 97.9 >8.2
Troponin I 0.821 0.038 0.743–0.883 96.8 63.5 >0
STEMI
CRP 0.946 0.024 0.870–0.984 89.7 88.6 >4.7
Lp(a) 0.888 0.036 0.796–0.948 84.0 84.9 >8.2
Troponin I 1.000 0.000 0.971–1.000 100.0 93.4 >0.01
∗P<. 05 versus CRP and troponin I in USAP patients, ∗∗P<. 05 versus troponin I in SAP patients, ∗∗∗P<0.001 versus troponin I in SAP patients.
for apoB/apoA and TG/HDL-c ratios (0.89 ± 0.03) and a
little bit lower AUC for Tc/HDL-c (0.87 ± 0.03) in USAP
patients. All three AUCs were signiﬁcantly higher than AUC
for LDL-c/HDL-c. The highest sensitivity and speciﬁcity
were observed for TG/HDL-c (80.0% and 82.4%, resp.),
and for Tc/HDL-c (73.3% and 71.4%, resp.). In STEMI
patients AUC for TG/HDL-c was the highest (0.91 ± 0.03),
followed by Tc/HDL-c (0.89 ± 0.03), and apoB/apoA (0.87
±0.04).Satisfactorysensitivity andspeciﬁcitywerenotedfor
TG/apoB (78.6% and 74.3%, resp.).
Multinomial logistic regression was used to adequately
predict (H = 203.12, df = 15, P<. 0005) a classiﬁcation of
cases into evaluated groups. This model classiﬁed evaluated
cases into the SAP group with an accuracy of 87.9%, control
group 82.6%, STEMI group with 78.4%, and USAP group
with 57.6%. Pearson (H = 337.53, df = 402, P = .99) and
Deviance (H = 173.73, df = 402, P = 1) conﬁrmed that this
model adequately ﬁted the data. Obtained model explained
about 82% of variation in evaluated groups. Likelihood ratio
test showed that Lp(a), apoA-I, TG, and CRP were predictors
signiﬁcantly (P<. 0005) contributing to the obtained model.
In comparison to the control group, Lp(a) (OR = 1.27, 95%
CI 1.11 to 1.45, P = .001) and apoA-I (OR = 8.295, CI
95% 1.22 to 56.35, P = .03) represented signiﬁcant, while
TG (OR = 0.23, 95% CI 0.04 to 1.52, P = 0.13), CRP
(OR = 1.36, 95% CI 0.97 to 1.90, P = .07), and neopterin
(OR = 1.05, 95% CI 0.96 to 1.15, P = .26) unsigniﬁcant
predictors in the SAP group. In the USAP group, Lp(a)
(OR = 1.29,95%CI1.12to1.48,P<. 0005),TG(OR = 3.32,
95%CI1.11to9.93,P = .03),apoA-I(OR = 0.004,95%CI0
to 0.37, P = .02), and CRP (OR = 1.56, 95% CI 1.11 to 2.18,
P = .01) were signiﬁcant predictors in comparison with the8 Cardiology Research and Practice
Table 7: The results of ROC curves analysis of atherogenic indexes in patients with ischemic heart disease.
AUC SE 95%CI Speciﬁcity Sensitivity Criterion
SAP
apoB/apoA
b 0.717 0.062 0.594–0.820 78.2 64.1 >0.93
LDL-c/apoB
d 0.771 0.062 0.652–0.865 52.7 76.9 ≥3.14
LDL-c/HDL-c 0.657 0.067 0.531–0.769 65.5 86.2 >3.24
Tc/HDL-cd 0.737 0.060 0.615–0.837 63.6 74.3 >5.08
TG/apoB
a,c 0.897 0.037 0.798–0.958 80.0 54.3 >1.19
TG/HDL-cd,e 0.883 0.040 0.781–0.949 87.0 55.9 >0.88
USAP
apoB/apoA
∗∗ 0.896 0.034 0.807–0.953 56.8 82.1 >1.08
LDL-c/apoB 0.745 0.063 0.635–0.836 68.2 76.9 >3.14
LDL-c/HDL-c 0.840 0.043 0.741–0.912 53.3 93.1 >3.40
Tc/HDL-c∗∗ 0.873 0.038 0.780–0.937 73.3 71.4 >4.97
TG/apoB 0.787 0.050 0.681–0.871 61.4 97.1 >1.85
TG/HDL-c∗ 0.896 0.034 0.808–0.953 80.0 82.4 >1.54
STEMI
apoB/apoA
A,C 0.879 0.040 0.778–0.945 81.0 41.0 >0.74
LDL-c/apoB 0.784 0.061 0.668–0.874 76.2 59.0 ≤3.33
LDL-c/HDL-c 0.800 0.052 0.686–0.887 36.4 100.0 >3.76
Tc/HDL-cB 0.889 0.038 0.790–0.952 45.5 77.1 >5.22
TG/apoB 0.849 0.045 0.742–0.923 78.6 74.3 >1.49
TG/HDL-cA,D 0.912 0.034 0.819–0.960 88.6 55.9 >0.88
aP<. 05 versus apoB/apoA, LDL-c/apoB and Tc/HDL-c, bP<. 01 versus LDL-c/HDL-c, cP<. 01 versus LDL-c/HDL-c, dP<. 001 versus LDL-c/HDL-c, eP<
.001 versus Tc/HDL-c, ∗P<. 05 versus LDL-c/apoB and LDL-c/HDL-c, ∗∗P<. 05 versus LDL-c/HDL-c, AP<. 05 versus LDL-c/apoB, BP<. 05 versus LDL-
c/HDL-c, CP<. 01 versus LDL-c/HDL-c, DP<. 01 versus TG/apoB.
controlgroup.Finally,inAIMgroup,onlyLp(a)(OR = 1.25,
95% CI 1.09 to 1.43, P = .001) and CRP (OR = 1.59, 95%
CI 1.14 to 2.22, P = .007) represented signiﬁcant predictors
comparing to the control group.
4. Discussion
The results of this study clearly demonstrated that none
of the studied standard and inﬂammatory markers showed
any signiﬁcant diﬀerence between statin-treated and non-
statin-treated patients. However, among lipid markers sig-
niﬁcantly lower apoA-I values were observed in all statin-
treated groups, as well as signiﬁcantly higher apoB ones
in STEMI(+) group in comparison with non-statin-treated
patients. Since almost all our patients diﬀered only in the
statintreatment,observeddiﬀerencesindicatethatthestatins
did not have the same eﬀects on all lipid markers, which
made them less sensitive markers.
In this multimarkers study, we showed that Lp(a) was the
marker with the best clinical accuracy, being the marker with
thelargestAUCandthebestsensitivityandspeciﬁcityamong
other lipid markers, as well as atherogenic indexes in all
patient groups. Of all inﬂammatory studied markers, hsCRP
was found to show signiﬁcantly higher AUC in comparison
withallotherinﬂammatorymarkersinpatientswithSTEMI.
In USAP patients, hsCRP also had the highest AUC although
this gained signiﬁcance only compared to TNF-α.
ThecomparisonofhsCRPandLp(a)ROCcurvesshowed
that AUC for Lp(a) was higher than for hsCRP in SAP and
USAP patients, and a signiﬁcant diﬀerence existed only in
USAP patients. In the STEMI group, hsCRP AUC was higher
thanLp(a)AUC,butthediﬀerencewasnotsigniﬁcant.These
ﬁndings showed that Lp(a) would be a marker with better
clinical accuracy, particularly in patients with USAP what
was also conﬁrmed by multinomial logistic regression.
Studies in the past [18] showed that the relationship
between coronary artery disease and Lp(a) was weak and
that Lp(a) may be a marker at only high levels. It could not
be used for widespread initial screening because the beneﬁts
might be small. Others have observed that the free apo(a)
had a better diagnostic test performance in atherosclerotic
risk assessment than Lp(a) testing [19]. Elevated Lp(a)
level is also considered to be the best single marker for
the presence of ischemic cerebrovascular disease, and the
increased portion of the smaller-molecular-weight apo(a)
isoforms in patients and individuals with a sonography
score >0 points toward an inherited predisposition for this
disease [13]. Erbaˇ gci et al. [20] showed that for optimal
cutoﬀ values for Lp(a) of 22.6 and 9.8mg/dL, the diagnostic
values of 0.612 and 0.596 in men and women, respectively,
withcoronaryheartdiseasewithorwithoutangiographically
demonstrable lesion were found. Our results showed that
Lp(a) had better AUC characteristics and may be more
useful than other multimarkers in SAP and USAP patients
especially in statin-treated ones.
It was also noted that optimal cutoﬀ levels for hsCRP in
women and men were found as 2.1 and 3.0mg/L with the
diagnostic values of 0.792 and 0.770, respectively. Contrary
to these results, we found much higher diagnostic values of
0.843, 0.957, and 0.888 for Lp(a) in SAP, USAP, and STEMI
patients, as well as higher diagnostic values of 0.859 and
0.946 for hsCRP in USAP and STEMI patients, and theCardiology Research and Practice 9
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Figure 1: ROC curves of lipid markers: ApoA-I, ApoB, Lp(a), LDL-c, oxLDL, and TG in STEMI patients (a), USAP patients (b), and SAP
patients (c).
diﬀerence between these two markers was signiﬁcant in the
USAP group. This ﬁnding is essential as, taking into account
optimal cutoﬀ level as >8.2 for Lp(a), Lp(a) is a better
independent predictor than CRP in SAP and USAP patients
on chronic treatment with statins. The Atherosclerosis Risk
in Communities (ARIC) study showed that including some
of the additional risk factors in the basic model containing
only traditional risk factors might improve predictivity. So,
they frequently found that the biggest contributors to the
highest increase in AUC, outside the basic model, were
albumin, ﬁbrinogen, and Lp(a) [21]. Bennet et al. [22]n o t e d
that baseline Lp(a) levels had little or no correlation with10 Cardiology Research and Practice
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Figure 2: ROC curves of inﬂammatory markers: CRP, ﬁbrinogen, iNOS, neopterin, NO2/N O 3,a n dT N F - α in STEMI patients (a), USAP
patients (b), and SAP patients (c).
known cardiovascular risk factors including age, sex, total
cholesterol level, and blood pressure. They concluded that
the levels of Lp(a) were highly stable within individuals
across the time and that there were independent, continuous
associations between Lp(a) levels and a risk of coronary
heart disease in a broad range of individuals. It seems that
nontraditional risk factors could become more useful in
predicting cardiovascular risk since clinical trials of statin
therapy have demonstrated that baseline or treated LDL-
c levels are only weakly associated with a net coronary
angiographic change or cardiovascular events [23]. Statins
reduce cardiovascular disease events and improve outcomes.Cardiology Research and Practice 11
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Figure 3: ROC curves of atherogenic indexes: ApoB/ApoA-I, LDL-c/ApoB, LDL-c/HDL-c, Tc/HDL-c, TG/ApoB, and TG/HDL-c in patients
with STEMI (a), USAP (b), and SAP (c).
Large clinical trials indicate that statin-treated individuals
have signiﬁcantly smaller chance of cardiovascular disease,
irirespective levels, and that the treatment is particularly
eﬀective among patients with high CRP levels. Beside the
reduction of lipid and CRP levels [23], statins express
additionaleﬀectsresultingintheimprovementofendothelial
function, antiinﬂammatory and antiproliferative response,
and the regression of human atherosclerotic lesions [23–
25]. Contrary to previous ﬁndings, in patients with type
IIa hypercholesterolemia, both atorvastatin and simvastatin,12 Cardiology Research and Practice
signiﬁcantly reduced Lp(a) levels but not apolipoprotein (a)
fragment levels after six-week treatment [26]. In spite of
these ﬁndings, we did not ﬁnd any signiﬁcant diﬀerence
in Lp(a) concentration between the statin-treated and non-
statin-treated patients, but we observed signiﬁcantly lower
apoA-I values in all patient groups, and signiﬁcantly higher
apoB in STEMI patients treated with statins.
In a prospective cohort study of more than 15000 healthy
women aged 45 years or older, treated with aspirin and
vitaminEandfollo wedupov era10-yearperiod,itwasnoted
that non-HDL-c and Tc/HDL-c were as good as, or better
than, apolipoprotein fraction in the prediction of future car-
diovascular events [27]. While these results support the use
of standard lipid measurements, rather than apolipoproteins
A-I and B in primary risk detection, in a randomized trial
of lovastatin, the levels of apoB and the ratio of apoB/apoA-
I were better predictors of future cardiovascular events than
LDL-c, when participants were receiving the treatment [28].
On this basis, it has been suggested that the measurement
of apoB could replace the current lipid status evaluation
among patients taking statins [29]. Since our study showed
that apoB signiﬁcantly changed only in STEMI patients, it is
not reliable for the evaluation ischemic heart disease patients
taking statins. According to our results, it can be Lp(a).
In conclusion, considering our results, the best marker in
assessingischemicheartdiseaseseemedtobeCRPinSTEMI,
TG/apoB in SAP, and Lp(a) in USAP patients, respectively.
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